Welcome to our dedicated page for BKV Corporation news (Ticker: BKV), a resource for investors and traders seeking the latest updates and insights on BKV Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BKV Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BKV Corporation's position in the market.
BKV reported its first earnings as a public company for Q3 2024, with net income of $12.9 million ($0.18 per diluted share) and Adjusted EBITDAX of $51.0 million. Total revenues were $173.1 million, down from $191.4 million in Q3 2023 due to lower natural gas prices and production volumes. The company achieved net cash from operations of $65.0 million and Adjusted Free Cash Flow of $19.6 million. Total net production was 762.6 MMcfe per day, with a de-levered balance sheet showing net debt of $158.7 million and a net leverage ratio of 0.8x.
BKV announced it will release its third quarter 2024 operational and financial results before markets open on Tuesday, November 12, 2024. The company will host a conference call at 10:00 a.m. ET the same day to discuss the results. Participants can join via phone at (877) 407-0779 (US) or (201) 389-0914 (international), with recommended dial-in 15 minutes early. A webcast will be available on BKV's investor relations website, along with a 60-day replay accessible through phone or website.
BKV (NYSE: BKV) has successfully closed its initial public offering (IPO) of 15,000,000 shares of common stock at $18.00 per share. The underwriters have a 30-day option to purchase an additional 2,250,000 shares at the IPO price. Trading of BKV shares began on the New York Stock Exchange on September 26, 2024, under the ticker symbol 'BKV'.
The IPO was led by Citigroup and Barclays as lead book-running managers, with Evercore ISI, Jefferies, and Mizuho acting as joint book-running managers. Several other firms, including KeyBanc Capital Markets and Truist Securities, served as senior co-managers and co-managers for the offering.
BKV has announced the pricing of its initial public offering (IPO) of 15,000,000 shares of common stock at $18.00 per share. The underwriters have a 30-day option to purchase an additional 2,250,000 shares at the IPO price. Trading will begin on the New York Stock Exchange on September 26, 2024, under the ticker symbol 'BKV'. The offering is expected to close on September 27, 2024.
Citigroup and Barclays are acting as lead book-running managers, with Evercore ISI, Jefferies, and Mizuho as joint book-running managers. Several other firms are serving as senior co-managers and co-managers for the offering. The IPO is being made through a prospectus, which will be available through the underwriters and the SEC website.
FAQ
What is the current stock price of BKV Corporation (BKV)?
What is the market cap of BKV Corporation (BKV)?
